Cytosorbents (CTSO) Set to Announce Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Cytosorbents to post earnings of ($0.12) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. The company had revenue of $8.67 million for the quarter, compared to the consensus estimate of $9.29 million. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Up 3.8 %

Cytosorbents stock opened at $0.84 on Thursday. The company has a quick ratio of 1.51, a current ratio of 1.77 and a debt-to-equity ratio of 0.11. Cytosorbents has a 12-month low of $0.78 and a 12-month high of $4.29. The firm’s fifty day moving average is $0.92 and its 200 day moving average is $1.15. The company has a market capitalization of $45.66 million, a PE ratio of -1.31 and a beta of 0.58.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright reiterated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Friday, March 15th. StockNews.com assumed coverage on shares of Cytosorbents in a research report on Wednesday, April 24th. They set a “hold” rating on the stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.